To reduce the cost, time and waste in screening for HIV and HBV infections a combined assay for HIV-1 and -2 antibodies and HBsAg has been developed. Monoclonal anti-HBs antibodies were co-immobilized with synthetic peptides representing immunodominant regions of HIV-1 and -2. The presence of anti-HIV antibodies in the samples was detected with alkaline phosphatase-labelled anti-human IgG and of HBsAg with horseradish peroxidase-labelled monoclonal anti-HBs antibodies by a sequential substrate reaction. In this assay, HBsAg was detectable in a concentration range between 0.25 and 0.30 U/ml and the results were available within 3 h. The specificity, tested on 5000 serum samples from blood donors after confirmation, was 99.8% for HBsAg and 99.5% for anti-HIV antibody detection. All serum samples taken from 600 HIV-1- and 115 HIV-2-infected individuals were correctly classified as reactive. The two-colour HBsAg-anti-HIV-1/-2 combination ELISA meets all the requirements of single parameter assays with regard to precision, stability and robustness.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0022-1759(93)90262-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study.
Lancet Gastroenterol Hepatol
December 2024
Department of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
Article Synopsis
- Chronic hepatitis B virus (HBV) is a significant global health concern, with existing treatments yielding low rates of HBsAg seroclearance; VIR-2218 (elebsiran) is being studied for its potential to reduce HBsAg levels.
- This phase 2 open-label study involved participants aged 18-65 from various countries who had chronic HBV but no cirrhosis, assessing the safety and effectiveness of VIR-2218 alone and in combination with pegylated interferon-alpha-2a.
- The study aimed to measure adverse events and clinical outcomes, including the reduction of HBsAg and long-term seroclearance rates among those receiving different treatment regimens over a period ranging from
Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study.
Eur J Pediatr
September 2024
Department of Pediatrics, Division of Pediatric Rheumatology, Faculty of Medicine, Gazi University, Ankara, Turkey.
Unlabelled: Rituximab (RTX) is a chimeric monoclonal antibody that targets the CD20 antigen on B cells and is used in various autoimmune disorders. In this study, we aimed to measure the awareness of pediatric rheumatologists about the use of RTX through a survey. Between February and March 2023, a 42-question survey was sent via email to pediatric rheumatology specialists in Turkey.
View Article and Find Full Text PDFCurrent and future use of antibody-based passive immunity to prevent or control HBV/HDV infections.
Antiviral Res
June 2024
Schwartz-Reisman Liver Research Centre, University Health Network, Toronto, ON, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada.
Article Synopsis
- Monoclonal antibody therapy is gaining traction for treating chronic hepatitis B (HBV) and hepatitis D (HDV), focusing on developing antibodies that target hepatitis B surface antigens (anti-HBs).
- Combining anti-HBs monoclonal antibodies with new anti-HBV drugs and immunomodulatory treatments may improve cure rates for HBV/HDV infections.
- The review examines how antibodies protect against HBV, the necessity of antibody functions beyond neutralization, and discusses clinical trial data on the effectiveness of passive antibody therapies paired with other innovative agents.
Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
J Neurol
July 2024
Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Dokuz Eylul University, 35330, Izmir, Turkey.
Background: The risk of hepatitis B virus (HBV) reactivation remains unclear in people with multiple sclerosis (MS) receiving ocrelizumab. We aimed to assess HBV seroprevalence and reactivation risk in MS patients on ocrelizumab and to evaluate the effectiveness of antiviral prophylaxis against HBV reactivation.
Methods: In this single-center, cross-sectional study, 400 people with MS receiving ocrelizumab were screened for HBV at baseline and antiviral prophylaxis was implemented based on serological results.
The Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Receiving Tocilizumab: A Systematic Review and Meta-Analysis.
Viruses
January 2024
Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung 204, Taiwan.
Background: Tocilizumab has demonstrated optimal efficacy and safety in patients with rheumatoid arthritis (RA) from clinical trials. However, the risk of hepatitis B virus reactivation (HBVr) in these patients remains uncertain because patients with underlying HBV have been excluded in phase III studies.
Methods: Systematical reviews were conducted on PubMed, Embase, and the Cochrane Central Register of Controlled Trials up to 21 February 2023.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!